Alectinib (BioDeep_00000175846)
human metabolite blood metabolite
代谢物信息卡片
9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H,6H,11H-benzo[b]carbazole-3-carbonitrile
化学式: C30H34N4O2 (482.2681624)
中文名称: 艾乐替尼
谱图信息:
最多检出来源 Homo sapiens(blood) 90%
分子结构信息
SMILES: CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=C(N1)C=C(C=C3)C#N)C2=O
InChI: InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01ED - Anaplastic lymphoma kinase (alk) inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C141136 - ALK Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:90936
- ChEBI: CHEBI:62268
- PubChem: 49806720
- HMDB: HMDB0248129
- DrugBank: DB11363
- ChEMBL: CHEMBL1738797
- Wikipedia: Alectinib
- chemspider: 26326738
- CAS: 1256580-46-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yumei Li, Shijin Lu, Ping Yao, Wenchuang Huang, Yong Huang, Ying Zhou, Ying Yuan, Shaochen Cheng, Fasheng Wu. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report.
Medicine.
2024 Jan; 103(3):e36992. doi:
10.1097/md.0000000000036992. [PMID: 38241569] - Ji Eun Park, Young-Ran Yoon, Chang Ho Kim, Jaehee Lee. Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report.
Thoracic cancer.
2022 04; 13(8):1224-1226. doi:
10.1111/1759-7714.14357. [PMID: 35191596] - J Wolf, Å Helland, I-J Oh, M R Migliorino, R Dziadziuszko, A Wrona, J de Castro, J Mazieres, F Griesinger, M Chlistalla, A Cardona, T Ruf, K Trunzer, V Smoljanovic, S Novello. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
ESMO open.
2022 02; 7(1):100333. doi:
10.1016/j.esmoop.2021.100333. [PMID: 35042152] - Yuji Mukai, Azusa Wakamoto, Tae Hatsuyama, Tatsunari Yoshida, Hideki Sato, Akihisa Fujita, Nobuo Inotsume, Takaki Toda. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Therapeutic drug monitoring.
2021 12; 43(6):772-779. doi:
10.1097/ftd.0000000000000895. [PMID: 33871406] - Hao-Chuan Ma, Yi-Hong Liu, Kai-Lin Ding, Yu-Feng Liu, Wen-Jie Zhao, Yan-Juan Zhu, Xue-Song Chang, Ya-Dong Chen, Zhen-Zhen Xiao, Ya-Ya Yu, Rui Zhou, Hai-Bo Zhang. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
BMC cancer.
2021 Nov; 21(1):1278. doi:
10.1186/s12885-021-08977-0. [PMID: 34836510] - Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, Haibo Zhang. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Journal of the National Comprehensive Cancer Network : JNCCN.
2021 11; 20(1):2-6. doi:
10.6004/jnccn.2021.7077. [PMID: 34763318] - Nobuhiko Hasegawa, Shinji Kohsaka, Kana Kurokawa, Yuki Shinno, Ikuko Takeda Nakamura, Toshihide Ueno, Shinya Kojima, Masahito Kawazu, Yoshiyuki Suehara, Muneaki Ishijima, Yasushi Goto, Yuki Kojima, Kan Yonemori, Takuo Hayashi, Tsuyoshi Saito, Takehito Shukuya, Fumiyuki Takahashi, Kazuhisa Takahashi, Hiroyuki Mano. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Cancer science.
2021 Oct; 112(10):4393-4403. doi:
10.1111/cas.15084. [PMID: 34310819] - Ondrej Bilek, Milos Holanek, Jan Jurica, Sona Stepankova, Jiri Vasina, Iveta Selingerova, Alexandr Poprach, Simona Borilova, Tomas Kazda, Igor Kiss, Lenka Zdrazilova-Dubska. Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient.
International immunopharmacology.
2021 Oct; 99(?):108012. doi:
10.1016/j.intimp.2021.108012. [PMID: 34339964] - Rujittika Mungmunpuntipantip, Viroj Wiwanitkit. Alectinib, COVID-19 and favipiravir.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2021 10; 27(7):1810. doi:
10.1177/10781552211035823. [PMID: 34424078] - Hadir M Maher, Aliyah Almomen, Nourah Z Alzoman, Shereen M Shehata, Ashwaq A Alanazi. Development and validation of UPLC-MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction.
Journal of pharmaceutical and biomedical analysis.
2021 Sep; 204(?):114276. doi:
10.1016/j.jpba.2021.114276. [PMID: 34325247] - Mehmet Hadi Akkus, Omur Kaman, Mutlu Dogan. Alectinib continuation during COVID 19 'antiviral' treatment: Risk or benefit?.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2021 Jul; 27(5):1251-1254. doi:
10.1177/10781552211020100. [PMID: 34038226] - Mo'tasem M Alsmadi, Nour M Al-Daoud, Mays M Jaradat, Saja B Alzughoul, Amani D Abu Kwiak, Salam S Abu Laila, Ayat J Abu Shameh, Mohammad K Alhazabreh, Sana'a A Jaber, Hala T Abu Kassab. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.
Biopharmaceutics & drug disposition.
2021 Jun; 42(6):263-284. doi:
10.1002/bdd.2282. [PMID: 33904202] - Giovanna Scarfone, Monica Fumagalli, Martina Imbimbo, Tommaso Ceruti, Fulvia Milena Cribiù, Eugenia Di Loreto, Maurizio D'Incalci, Federica Facchin, Camilla Fontana, Marina C Garassino, Fedro A Peccatori, Nicola Persico, Diego Signorelli, Massimo Zucchetti. First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2021 05; 16(5):873-877. doi:
10.1016/j.jtho.2021.02.005. [PMID: 33795207] - Stefanie L Groenland, Dieuwertje R Geel, Julie M Janssen, Niels de Vries, Hilde Rosing, Jos H Beijnen, Jacobus A Burgers, Egbert F Smit, Alwin D R Huitema, Neeltje Steeghs. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
Clinical pharmacology and therapeutics.
2021 02; 109(2):394-402. doi:
10.1002/cpt.1989. [PMID: 32686074] - Flávia Amaral Duarte, Leonardo Brand Rodrigues, Flávia Rocha Paes, Paulo Henrique Costa Diniz, Helena Flávia Cuba de Almada Lima. Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report.
BMC pulmonary medicine.
2021 Jan; 21(1):43. doi:
10.1186/s12890-020-01390-6. [PMID: 33509141] - Michele Montrone, Annamaria Catino, Vincenzo O Palmieri, Vito Longo, Domenico Galetta. Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib.
European journal of cancer (Oxford, England : 1990).
2020 10; 138(?):109-112. doi:
10.1016/j.ejca.2020.07.030. [PMID: 32871524] - Johannes Noé, Alex Lovejoy, Sai-Hong Ignatius Ou, Stephanie J Yaung, Walter Bordogna, Daniel M Klass, Craig A Cummings, Alice T Shaw. ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2020 04; 15(4):601-608. doi:
10.1016/j.jtho.2019.10.015. [PMID: 31712133] - Zhaona Li, Pupu Li, Bing Yan, Qiongqiong Gao, Xiangli Jiang, Zhongli Zhan, Qingna Yan, Analyn Lizaso, Chun Huang. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Thoracic cancer.
2020 01; 11(1):176-180. doi:
10.1111/1759-7714.13259. [PMID: 31766077] - Jia Hu, Baoshi Zhang, Fangfang Yao, Yan Fu, Dianjun Chen, Donghui Li, Nan Du, Analyn Lizaso, Jinlei Song, Lu Zhang, Xiaosong Li. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Therapeutic advances in respiratory disease.
2020 Jan; 14(?):1753466620935770. doi:
10.1177/1753466620935770. [PMID: 32600123] - Go Makimoto, Kadoaki Ohashi, Shuta Tomida, Kazuya Nishii, Takehiro Matsubara, Hiroe Kayatani, Hisao Higo, Kiichiro Ninomiya, Akiko Sato, Hiromi Watanabe, Hirohisa Kano, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Minoru Takata, Yoshinobu Maeda, Katsuyuki Kiura. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2019 11; 14(11):2009-2018. doi:
10.1016/j.jtho.2019.07.017. [PMID: 31374369] - Vito Longo, Anna Maria Catino, Michele Montrone, Francesco Pesola, Pamela Pizzutilo, Gabriela Delbene, Pietro Gatti, Annunziata Ferrante, Domenico Galetta. Development of Complex Renal Cysts during Crizotinib Treatment and Also during Alectinib Treatment: A Possible Drug Class Effect?.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2019 08; 14(8):e170-e172. doi:
10.1016/j.jtho.2019.03.010. [PMID: 31345340] - Jakub Hofman, Ales Sorf, Dimitrios Vagiannis, Simona Sucha, Eva Novotna, Sarah Kammerer, Jan-Heiner Küpper, Martina Ceckova, Frantisek Staud. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
Drug metabolism and disposition: the biological fate of chemicals.
2019 07; 47(7):699-709. doi:
10.1124/dmd.119.086975. [PMID: 31068367] - D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis, Byoung Chul Cho, Li Zhang, Denis Moro-Sibilot, Ting Liu, Walter Bordogna, Bogdana Balas, Barbara Müller, Alice T Shaw. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2019 07; 14(7):1233-1243. doi:
10.1016/j.jtho.2019.03.007. [PMID: 30902613] - G D Marijn Veerman, Mei H Lam, Ron H J Mathijssen, Stijn L W Koolen, Peter de Bruijn. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Apr; 1113(?):37-44. doi:
10.1016/j.jchromb.2019.03.011. [PMID: 30889498] - Takeshi Hirota, Shota Muraki, Ichiro Ieiri. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Clinical pharmacokinetics.
2019 04; 58(4):403-420. doi:
10.1007/s40262-018-0689-7. [PMID: 29915924] - Peter N Morcos, Yumi Cleary, Carolina Sturm-Pellanda, Elena Guerini, Markus Abt, Massimiliano Donzelli, Faye Vazvaei, Bogdana Balas, Neil Parrott, Li Yu. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Journal of clinical pharmacology.
2018 12; 58(12):1618-1628. doi:
10.1002/jcph.1286. [PMID: 30052269] - Rolf W Sparidans, Wenlong Li, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.
Journal of pharmaceutical and biomedical analysis.
2018 Nov; 161(?):136-143. doi:
10.1016/j.jpba.2018.08.038. [PMID: 30149189] - P Ramachandran, R Morcus, M Tahir, I Onukogu, B Spinowitz, Jen C Wang. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
Journal of medical case reports.
2018 Oct; 12(1):303. doi:
10.1186/s13256-018-1849-y. [PMID: 30336782] - Sumanta K Pal, Paulo Bergerot, Nazli Dizman, Cristiane Bergerot, Jacob Adashek, Russell Madison, Jon H Chung, Siraj M Ali, Jeremy O Jones, Ravi Salgia. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
European urology.
2018 07; 74(1):124-128. doi:
10.1016/j.eururo.2018.03.032. [PMID: 29685646] - Han Wang, Yao Wang, Wentao Guo, Bin Du, Xiaobing Huang, Riping Wu, Baoyu Yang, Xiaoyan Lin, Yilan Wu. Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.
Drug design, development and therapy.
2018; 12(?):1183-1193. doi:
10.2147/dddt.s147104. [PMID: 29785088] - Masafumi Saiki, Fumiyoshi Ohyanagi, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Hironori Ninomiya, Yuichi Ishikawa, Makoto Nishio. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
Japanese journal of clinical oncology.
2017 Dec; 47(12):1189-1192. doi:
10.1093/jjco/hyx133. [PMID: 28977547] - Kageaki Taima, Hisashi Tanaka, Yoshihito Tanaka, Masamichi Itoga, Shingo Takanashi, Sadatomo Tasaka. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
Internal medicine (Tokyo, Japan).
2017 Sep; 56(17):2321-2324. doi:
10.2169/internalmedicine.8445-16. [PMID: 28794366] - Ke Yang, Yifan Chen, Kenneth Kin Wah To, Fang Wang, Delan Li, Likun Chen, Liwu Fu. Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.
Experimental & molecular medicine.
2017 03; 49(3):e303. doi:
10.1038/emm.2016.168. [PMID: 28303028] - Peter N Morcos, Katrijn Bogman, Stanislas Hubeaux, Carolina Sturm-Pellanda, Thorsten Ruf, Walter Bordogna, Sophie Golding, Ali Zeaiter, Markus Abt, Bogdana Balas. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
Cancer chemotherapy and pharmacology.
2017 03; 79(3):559-568. doi:
10.1007/s00280-017-3253-5. [PMID: 28243683] - Peter N Morcos, Li Yu, Katrijn Bogman, Mika Sato, Hisakazu Katsuki, Kosuke Kawashima, David J Moore, Matt Whayman, Keith Nieforth, Katja Heinig, Elena Guerini, Dieter Muri, Meret Martin-Facklam, Alex Phipps. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Xenobiotica; the fate of foreign compounds in biological systems.
2017 Mar; 47(3):217-229. doi:
10.1080/00498254.2016.1179821. [PMID: 27180975] - Katja Heinig, Denis Herzog, Luca Ferrari, Daniela Fraier, Kazuhiro Miya, Peter N Morcos. LC-MS/MS determination of alectinib and its major human metabolite M4 in human urine: prevention of nonspecific binding.
Bioanalysis.
2017 Mar; 9(5):459-468. doi:
10.4155/bio-2016-0284. [PMID: 28176528] - Xiang-Xin Huang, Yun-Xuan Li, Xiang-Yu Li, Xiao-Xia Hu, Peng-Fei Tang, Guo-Xin Hu. An UPLC-MS/MS method for the quantitation of alectinib in rat plasma.
Journal of pharmaceutical and biomedical analysis.
2017 Jan; 132(?):227-231. doi:
10.1016/j.jpba.2016.10.010. [PMID: 27768922] - Giulio Metro, Gianluigi Lunardi, Chiara Bennati, Pietro Chiarini, Isabella Sperduti, Biagio Ricciuti, Luca Marcomigni, Cinzia Costa, Lucio Crinò, Piero Floridi, Stefania Gori, Rita Chiari. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
Journal of neuro-oncology.
2016 09; 129(2):355-61. doi:
10.1007/s11060-016-2184-z. [PMID: 27324494] - Katja Heinig, Kazuhiro Miya, Tomonori Kamei, Elena Guerini, Daniela Fraier, Li Yu, Surendra Bansal, Peter N Morcos. Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment.
Bioanalysis.
2016 Jul; 8(14):1465-79. doi:
10.4155/bio-2016-0068. [PMID: 27329641] - Hiroaki Aikawa, Mitsuhiro Hayashi, Shoraku Ryu, Makiko Yamashita, Naoto Ohtsuka, Masanobu Nishidate, Yasuhiro Fujiwara, Akinobu Hamada. Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging.
Scientific reports.
2016 Mar; 6(?):23749. doi:
10.1038/srep23749. [PMID: 27026287] - Satoshi Ikeda, Hiroshige Yoshioka, Machiko Arita, Takahiro Sakai, Naoyuki Sone, Akihiro Nishiyama, Takashi Niwa, Machiko Hotta, Tomohiro Tanaka, Tadashi Ishida. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Japanese journal of clinical oncology.
2015 Feb; 45(2):221-4. doi:
10.1093/jjco/hyu183. [PMID: 25398579] - Tatsushi Kodama, Masami Hasegawa, Kenji Takanashi, Yuji Sakurai, Osamu Kondoh, Hiroshi Sakamoto. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Cancer chemotherapy and pharmacology.
2014 Nov; 74(5):1023-8. doi:
10.1007/s00280-014-2578-6. [PMID: 25205428]